Previous 10 | Next 10 |
2023-12-18 14:00:05 ET Summary Eli Lilly and Company wants to acquire POINT Biopharma Global Inc. with a tender offer of $12.5/share, which represented an 87% premium. POINT Biopharma Global is trading at $12.45, just $0.05 above the take-out price, and the tender offer could wrap...
2023-12-18 09:22:49 ET More on Lantheus, POINT Biopharma Global, etc. POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Tran...
2023-12-17 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-12 08:36:13 ET Summary Lantheus experienced tremendous growth in the last two years thanks to the approval of a new imaging agent called PYLARIFY. The company now faces several catalysts including the approval of PYLARIFY in Europe and the commercialization of PNT2002 and ...
2023-11-03 06:10:25 ET Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Conference Call November 02, 2023, 08:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President ...
2023-11-02 07:09:05 ET More on Lantheus Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover Lantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade) Lantheus: Not Quite Ready To Take The Plunge ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year period GAAP net income of $132.0 million for the third quarter 2023, compared to GAAP net income of $61.2 million in the prior year period GAAP fully diluted net i...
Lantheus Holdings Inc. (LNTH) is expected to report $1.19 for Q3 2023
2023-11-01 13:02:03 ET More on Lantheus Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover Lantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade) Lantheus: Not Quite Ready To Take The Plunge ...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...
BEDFORD, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced its acqu...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...